Fulcrum Therapeutics Inc’s recently made public that its Director Gould Robert J unloaded Company’s shares for reported $0.18 million on Jan 02 ’26. In the deal valued at $11.87 per share,15,000 shares were sold. As a result of this transaction, Gould Robert J now holds 469,864 shares worth roughly $4.63 million.
Then, Oltmans Curtis Gale sold 3,452 shares, generating $44,600 in total proceeds. Upon selling the shares at $12.92, the Chief Legal Officer now owns 10,252 shares.
Before that, CURTIS G OLTMANS bought 3,452 shares. Fulcrum Therapeutics Inc shares valued at $44,876 were divested by the Officer at a price of $13.00 per share.
Truist initiated its Fulcrum Therapeutics Inc [FULC] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late July from “a Neutral” to “a Buy”. Leerink Partners also remained covering FULC and has increased its forecast on May 23, 2025 with a “an Outperform” recommendation from previously “Market perform” rating. Cantor Fitzgerald revised its rating on May 15, 2025. It rated FULC as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of FULC
On Monday, Fulcrum Therapeutics Inc [NASDAQ:FULC] saw its stock fall -2.57% to $9.85. Over the last five days, the stock has lost -9.80%. Fulcrum Therapeutics Inc shares have risen nearly 101.43% since the year began. Nevertheless, the stocks have fallen -12.91% over the past one year.
How much short interest is there in Fulcrum Therapeutics Inc?
A steep rise in short interest was recorded in Fulcrum Therapeutics Inc stocks on 2025-12-15, dropping by -0.57 million shares to a total of 2.99 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 3.56 million shares. There was a decline of -19.05%, which implies that there is a negative sentiment for the stock.
